Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J.V. McMurray, John; D. Solomon, Scott; E. Inzucchi, Silvio; Køber, Lars; Kosiborod, Mikhail; A. Martínez, Felipe; Ponikowski, Piotr; S. Sabatine, Marc; S. Anand, Inder; Bělohlávek, Jan; Böhm, Michael; Chiang, Chern‐En; Chopra, Vijay; A. de Boer, Rudolf; S. Desai, Akshay; Díez, Mirta; Dróżdż, Jarosław; Dukát, Andrej; Ge, Junbo; G. Howlett, Jonathan; Katova, Tzvetana; Kitakaze, Masafumi; Ljungman, Charlotta; Merkely, Béla; Carlos Nicolau, José; O’Meara, Eileen; C. Petrie, Mark; Nguyễn Vinh, Pham; Schou, Morten; Н. Терещенко, С.; Verma, Subodh; Held, Claes; L. DeMets, David; F. Docherty, Kieran; S. Jhund, Pardeep; Bengtsson, Olof; Sjöstrand, Mikaela; Langkilde, Anna-Maria

doi:10.1056/nejmoa1911303

Public

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Published in New England Journal of Medicine • Sep 19, 2019

Authors:

John J.V. McMurray

Scott D. Solomon

Silvio E. Inzucchi

Abstract

BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with establishe...

Subject

Dapagliflozin

Ejection fraction

Heart failure

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!